FMR1 and fragile X syndrome: These results indicate that BA-10, a novel compound with improved pharmacokinetic properties with respect to known 5-HT7 receptor agonists, is able to reverse mGluR-LTD in wild-type mice and to rescue synaptic plasticity in Fmr1 KO mice, thus might be envisaged as a new pharmacological tool for Fragile X Syndrome.